Indication

Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

Medicine details

Medicine name:
baricitinib (Olumiant)
SMC ID:
SMC2337
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Skin
Submission type
Full
Publication due date:
14 June 2021
SMC meeting date:
04 May 2021
Patient group submission deadline:
05 April 2021